Is the price fair?
What VTRS's price assumes
Today's price asks for −4.9% free cash flow growth a year; over the last three years Viatris delivered −3.6%, less than the record.
1.08
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 11%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- −4.9%
Growth the price implies · The price pays for −4.9% free cash flow growth a year for a decade; the business has delivered −3.6% a year over the last three.
- EV / sales
- 1.81
EV / sales
Details›
- EV / EBIToperating margin −0.59%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 1.81
- Free cash flow, trailing twelve months
- $1.95B
- Market capitalisation
- $17.9B
- 3-year revenue growth
- −1.9%
- 3-year free cash flow growth
- −3.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #7 of 28 by Smart Score